Last reviewed · How we verify
CIK and γδ T
At a glance
| Generic name | CIK and γδ T |
|---|---|
| Sponsor | Beijing Doing Biomedical Co., Ltd. |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Clinical Study on the Safety, Tolerance, and Preliminary Efficacy of γδ-T Cell Injection in the Treatment of Advanced Bladder Cancer
- Safety and Efficacy of γδ T Cell Against Gastric Cancer (PHASE1, PHASE2)
- Safety and Efficiency of γδ T Cell Against Non Small Lung Cancer ( Without EGFR Mutation) (PHASE1, PHASE2)
- Safety and Efficiency of γδ T Cell Against Breast Cancer(Her-, er-, and pr-) (PHASE1, PHASE2)
- Safety and Efficiency of γδ T Cell Against Hepatocellular Liver Cancer (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CIK and γδ T CI brief — competitive landscape report
- CIK and γδ T updates RSS · CI watch RSS
- Beijing Doing Biomedical Co., Ltd. portfolio CI